Structure Therapeutics Inc. (NASDAQ:GPCR - Get Free Report)'s stock price rose 9.3% on Friday . The stock traded as high as $33.04 and last traded at $32.90. Approximately 607,312 shares changed hands during trading, a decline of 22% from the average daily volume of 781,340 shares. The stock had previously closed at $30.10.
Analyst Ratings Changes
A number of equities analysts recently commented on the company. Cantor Fitzgerald reiterated an "overweight" rating and set a $65.00 price target on shares of Structure Therapeutics in a report on Monday, September 23rd. Morgan Stanley initiated coverage on Structure Therapeutics in a research report on Monday, September 23rd. They issued an "overweight" rating and a $118.00 price target on the stock. Finally, JMP Securities lowered their price objective on shares of Structure Therapeutics from $91.00 to $86.00 and set a "market outperform" rating for the company in a research report on Friday, August 9th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $86.80.
Read Our Latest Research Report on Structure Therapeutics
Structure Therapeutics Trading Up 11.8 %
The stock's fifty day moving average is $38.94 and its two-hundred day moving average is $39.59. The firm has a market cap of $1.93 billion, a P/E ratio of -43.24 and a beta of -3.23.
Institutional Trading of Structure Therapeutics
A number of hedge funds and other institutional investors have recently modified their holdings of GPCR. Sandia Investment Management LP bought a new stake in Structure Therapeutics in the 2nd quarter worth approximately $39,000. Assetmark Inc. lifted its holdings in shares of Structure Therapeutics by 120.0% in the third quarter. Assetmark Inc. now owns 1,318 shares of the company's stock worth $58,000 after buying an additional 719 shares in the last quarter. Quarry LP purchased a new position in Structure Therapeutics during the 2nd quarter valued at approximately $79,000. Mirae Asset Global Investments Co. Ltd. raised its stake in Structure Therapeutics by 60.1% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,784 shares of the company's stock valued at $158,000 after purchasing an additional 1,420 shares in the last quarter. Finally, Dearborn Partners LLC bought a new stake in Structure Therapeutics during the third quarter worth approximately $202,000. 91.78% of the stock is owned by hedge funds and other institutional investors.
About Structure Therapeutics
(
Get Free Report)
Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Structure Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Structure Therapeutics wasn't on the list.
While Structure Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
